Daxor Corporation (NYSEAMERICAN: DXR) is having yet another incredible start to the trading session in the pre-market hours this morning, expanding on recent and robust gains that we’ve seen on the stock. Ultimately, the gains were the result of a recent announcement explaining the presentation of new data. Today, we’ll talk about the presentation, what we’re seeing from the stock, and what we’ll be watching with regard to DXR ahead.
DXR Continues Toward The Top On New Data
As mentioned above, Daxor has had an overwhelmingly strong time in the market as of late, and those gains are continuing in the pre-market this morning. Ultimately, the drastic climb that we’ve seen in the stock as of late started in Wednesday’s trading session when the company announced the presentation of new research.
In a press release issued early Wednesday morning, DXR announced the presentation of new research that highlighted the significant benefits to patient outcomes through individualization of care that is guided by blood volume analysis. The study was conducted by John E Strobeck, MD, PhD, and Wayne L. Miller MD, PhD, of the Mayo Clinic. The data was presented at the American College of Cardiology 2018 Scientific Session in a presentation titled “Cardiotoxicity, Cardiomyopathies and Heart Failure Readmissions”. In a statement, Michael Feldschuh, CEO at DXR, had the following to offer:
This pioneering study confirms that Daxor’s rapid non-invasive diagnostic can be essential to improving outcomes and the related economic costs of hospitalized heart failure. Heart failure is one of the greatest challenges our healthcare system faces – it affects over six million Americans and is responsible for one in nine deaths. Mortality rates for heart failure have been rising and the costs to our system already exceed 30 billion dollars per year. We expect the urgent need for an effective solution will to lead to increased interest in our technology and further confirmatory studies.
What WE’re Seeing From The Stock
As investors, one of the first lessons that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. After all, new positive data surrounding the company’s work in blood volume analysis is great news. So, it’s no surprise to see that DXR is making a run for the top today. Currently (8:25), DXR is trading at $17.50 per share after a gain of $4.15 per share or 31.09% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on DXR. In particular, we’re interested in following the story surrounding the company’s work in the blood volume analysis space. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!